Real-world Effectiveness of Asciminib and Treatment Patterns in Patients With Chronic Myeloid Leukemia With T315I Mutation - a Chart Review Study of Patients Treated in the Asciminib Managed Access Program (MAP)
Clinical trial NCT06211153 · COMPLETED
Trial details
- NCT number
- NCT06211153
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2021-12-31
- Primary completion
- 2022-12-15
- Enrollment
- 31
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.